Upadacitinib to improve anxiety in patients with adalimumab-treated psoriatic arthritis: study protocol for a randomized controlled trial
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- Extent
-
1 Online-Ressource.
- Language
-
Englisch
- Bibliographic citation
-
Upadacitinib to improve anxiety in patients with adalimumab-treated psoriatic arthritis: study protocol for a randomized controlled trial ; volume:25 ; number:1 ; day:5 ; month:9 ; year:2024 ; pages:1-9 ; date:12.2024
Trials ; 25, Heft 1 (5.9.2024), 1-9, 12.2024
- Creator
-
Liao, Junlan
Wang, Ziyu
Zhang, Jianyong
Tan, Haibo
Zhang, Zhihao
Zhang, Shan
Hu, Shasha
Geng, Hongling
Zhan, Zhiying
Wei, Jiaxin
Li, Zhiling
Jia, Ertao
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1186/s13063-024-08429-7
- URN
-
urn:nbn:de:101:1-2411212225391.352059453550
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:34 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Liao, Junlan
- Wang, Ziyu
- Zhang, Jianyong
- Tan, Haibo
- Zhang, Zhihao
- Zhang, Shan
- Hu, Shasha
- Geng, Hongling
- Zhan, Zhiying
- Wei, Jiaxin
- Li, Zhiling
- Jia, Ertao
- SpringerLink (Online service)
Other Objects (12)
Improvement in Patient-Reported Outcomes in Patients with Psoriatic Arthritis Treated with Upadacitinib Versus Placebo or Adalimumab: Results from SELECT-PsA 1
Rheumatoide Arthritis: Upadacitinib im Vergleich gegen Plazebo und Adalimumab
Lymph node and pulmonary tuberculosis during upadacitinib treatment in a psoriatic arthritis patient
Refractory necrotizing scleritis successfully treated with adalimumab
Adalimumab Biosimilar-Induced Severe Paradoxical Palmoplantar Pustulosis in a Patient with Psoriasis and Psoriatic Arthritis Successfully Treated with Ixekizumab
Time to response for clinical and patient-reported outcomes in patients with psoriatic arthritis treated with tofacitinib, adalimumab, or placebo
IgA Nephropathy in a Patient Treated with Adalimumab
Duodenal Crohn’s disease successfully treated with adalimumab
Adalimumab in the management of psoriasis and psoriatic arthritis: Results from a Delphi investigation
Benefit–Risk Analysis of Upadacitinib Compared with Adalimumab in the Treatment of Patients with Moderate-to-Severe Rheumatoid Arthritis
Malignancy in the Upadacitinib Clinical Trials for Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis, and Non-radiographic Axial Spondyloarthritis
Addition or removal of concomitant methotrexate alters adalimumab effectiveness in rheumatoid arthritis but not psoriatic arthritis
Improvement in Patient-Reported Outcomes in Patients with Psoriatic Arthritis Treated with Upadacitinib Versus Placebo or Adalimumab: Results from SELECT-PsA 1
Rheumatoide Arthritis: Upadacitinib im Vergleich gegen Plazebo und Adalimumab
Lymph node and pulmonary tuberculosis during upadacitinib treatment in a psoriatic arthritis patient
Refractory necrotizing scleritis successfully treated with adalimumab
Adalimumab Biosimilar-Induced Severe Paradoxical Palmoplantar Pustulosis in a Patient with Psoriasis and Psoriatic Arthritis Successfully Treated with Ixekizumab
Time to response for clinical and patient-reported outcomes in patients with psoriatic arthritis treated with tofacitinib, adalimumab, or placebo
IgA Nephropathy in a Patient Treated with Adalimumab
Duodenal Crohn’s disease successfully treated with adalimumab
Adalimumab in the management of psoriasis and psoriatic arthritis: Results from a Delphi investigation
Benefit–Risk Analysis of Upadacitinib Compared with Adalimumab in the Treatment of Patients with Moderate-to-Severe Rheumatoid Arthritis
Malignancy in the Upadacitinib Clinical Trials for Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis, and Non-radiographic Axial Spondyloarthritis
Addition or removal of concomitant methotrexate alters adalimumab effectiveness in rheumatoid arthritis but not psoriatic arthritis
Improvement in Patient-Reported Outcomes in Patients with Psoriatic Arthritis Treated with Upadacitinib Versus Placebo or Adalimumab: Results from SELECT-PsA 1
Rheumatoide Arthritis: Upadacitinib im Vergleich gegen Plazebo und Adalimumab
Lymph node and pulmonary tuberculosis during upadacitinib treatment in a psoriatic arthritis patient
Refractory necrotizing scleritis successfully treated with adalimumab
Adalimumab Biosimilar-Induced Severe Paradoxical Palmoplantar Pustulosis in a Patient with Psoriasis and Psoriatic Arthritis Successfully Treated with Ixekizumab
Time to response for clinical and patient-reported outcomes in patients with psoriatic arthritis treated with tofacitinib, adalimumab, or placebo
IgA Nephropathy in a Patient Treated with Adalimumab
Duodenal Crohn’s disease successfully treated with adalimumab
Adalimumab in the management of psoriasis and psoriatic arthritis: Results from a Delphi investigation
Benefit–Risk Analysis of Upadacitinib Compared with Adalimumab in the Treatment of Patients with Moderate-to-Severe Rheumatoid Arthritis
Malignancy in the Upadacitinib Clinical Trials for Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis, and Non-radiographic Axial Spondyloarthritis